Table 3.
Overall ex vivo sensitivity for P. vivax with ≥80% and <80% of parasites at ring stage at the start of the assay
| Drug | Indicated values for P. vivax isolates with: |
|||
|---|---|---|---|---|
| ≥80% rings |
60–80% rings |
|||
| n (%)a | Median IC50 (range) in nM and P valueb | n (%)a | Median IC50 (range) in nM and P valueb | |
| Chloroquine | 11/11 (100) | 45.7 (12.9–143.4) | 7/7 (100) | 50.8 (23.6–68.6) |
| Amodiaquine | 11/11 (100) | 17.1 (7.1–25.8) | 7/7 (100) | 13.4 (7.5–17.0) |
| Piperaquine | 11/11 (100) | 13.1 (4.0–28.7) | 7/7 (100) | 21.9 (5.2–28.9) |
| Artesunate | 10/11 (91) | 3.5 (1.6–6.2) | 5/7 (71) | 4.9 (3.6–6.3) |
| DHA | 10/11 (91) | 4.8 (2.8–6.8), P = 0.029 | 6/7 (86) | 6.0 (4.3–11.5), P = 0.225 |
| OZ277 | 10/11 (91) | 5.2 (1.7–8.7), P = 0.037 | 6/7 (86) | 4.0 (1.8–16.3), P = 0.500 |
| OZ439 | 10/11 (91) | 3.7 (1.3–8.8), P = 0.285 | 6/7 (86) | 4.8 (2.6–10.3), P = 0.892 |
| Artemisone | 10/11 (91) | 0.6 (0.3–3.4), P = 0.005 | 5/7 (71) | 0.9 (0.6–4.1), P = 0.043 |
| Artemiside | 10/11 (91) | 2.8 (0.7–14.4), P = 0.386 | 5/7 (71) | 2.9 (0.5–13.3), P = 0.893 |
a
Total number of assays with acceptable IC50s/total number of assays (percentage).
b
P values are from a comparison with values for artesunate (Wilcoxon signed-rank test).